Skip to main
ANGO
ANGO logo

AngioDynamics (ANGO) Stock Forecast & Price Target

AngioDynamics (ANGO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AngioDynamics Inc. is experiencing growth in its customer base within both the outpatient behavioral health (OBL) and hospital settings, which contributes to an increase in average selling price (ASP). The company's gross margin improvement efforts, set for completion by January 2026, are expected to enhance profitability, supported by a favorable revenue mix that leans towards higher Med-Tech revenues, currently reflecting a gross margin of 52.5%. Furthermore, management anticipates ongoing growth driven by new customer acquisitions, increased utilization in existing accounts, and successful pricing strategies for its product offerings.

Bears say

AngioDynamics Inc. faces a challenging outlook due to expected tariff headwinds of $4 million to $6 million affecting its financial guidance, which could compress profit margins. Additionally, management anticipates increased pressure on inventory in the second half of fiscal year 2026 due to rising raw material prices, potentially impacting operational efficiency and cost management. While recent performance in capital sales indicates a favorable demand trend, the reliance on these sales raises concerns about the sustainability of revenues, particularly for disposable products moving forward.

AngioDynamics (ANGO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AngioDynamics (ANGO) Forecast

Analysts have given AngioDynamics (ANGO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, AngioDynamics (ANGO) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AngioDynamics (ANGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.